Severe Asthma Management

Publication Date: October 1, 2019

Key Points

Key Points

Following the recent appearance of new anti-interleukin biologic agents and standardization of sputum eosinophil counts and exhaled nitric oxide fraction (FENO), ATS/ERS have added recommendations for these agents for adults with severe uncontrolled asthma and modified certain other recommendations from the 2014 guideline.

Treatment

...Treatmen...

...Table 1. Recommend...

...ti-IL-5 strategy as add-on therapy for adult pat...

...that a blood eosinophil cut-point ≥150 µL...

...a blood eosinophil cut-off ≥260 µL−1 to...

...using a FENO cut-off ≥19.5 ppb to identi...

...r children, adolescents and adults with severe ast...

...suggest a trial of macrolide treatment to reduce...

...suggest against the use of chronic macroli...

...t dupilumab as add-on therapy for adult patients...


...e 2. Monoclonal Antibodies for Severe AsthmaHa...